An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients With Advanced Renal Cell Carcinoma.
Phase of Trial: Phase III
Latest Information Update: 06 Jan 2015
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Bayer
- 21 Nov 2012 New source identified and integrated (German Clinical Trials Register, DRKS00004072).
- 09 Jun 2009 Actual end date changed from Oct 2008 to Nov 2008 as reported by ClinicalTrials.gov.
- 30 Nov 2008 Status changed from active, no longer recruiting to completed, reported by ClinicalTrials.gov.